The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -13,722 | -17,516 | -12,888 | -29,447 |
| Stock-based compensation expense | 1,605 | 1,043 | 3,976 | 3,035 |
| Non-cash operating lease expense | 58 | 57 | 56 | 88 |
| Accretion of discounts on marketable securities, net | 305 | 511 | 523 | 1,240 |
| Depreciation and amortization expense | 38 | 30 | 29 | 38 |
| In-process research and development, related party | - | 0 | 0 | 0 |
| Unrealized foreign currency transaction loss | -21 | 5 | 1 | -24 |
| Prepaid expenses and other current assets | -929 | 706 | 1,382 | -1,272 |
| Long-term liabilities | - | 0 | 0 | 0 |
| Accounts payable and accrued liabilities, related party-Related Party | - | - | 0 | 0 |
| Other long-term assets | 0 | 0 | 162 | 1,352 |
| Accounts payable | -1,409 | 1,792 | -393 | 165 |
| Accounts payable and accrued liabilities, related party | - | 0 | - | - |
| Accrued expenses and other current liabilities | -1,532 | 220 | -792 | 944 |
| Operating lease liabilities | -62 | -39 | -59 | -109 |
| Net cash used in operating activities | -14,379 | -15,635 | -12,139 | -26,582 |
| Purchases of property and equipment | - | 0 | 109 | 77 |
| Purchases of marketable securities | 44,855 | 4,996 | 23,712 | 79,370 |
| Proceeds from maturities of marketable securities | 31,900 | 30,534 | 39,081 | 41,482 |
| Issuance of promissory loan in connection with asset acquisition | - | 0 | 0 | 0 |
| Cash paid in connection with asset acquisition, net of cash received | - | 0 | 0 | 0 |
| Net cash used in investing activities | -12,955 | 25,538 | 15,260 | -37,965 |
| Proceeds from exercise of stock options | 5 | 65 | 0 | 0 |
| Pre-funded warrant issuance costs | - | 86 | - | - |
| Proceeds from issuance of common stock in private placement, net of issuance costs | - | 0 | 0 | 0 |
| Net cash provided by financing activities | 5 | -21 | 0 | 0 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 | 0 | 0 |
| Net change in cash and cash equivalents | -27,329 | 9,882 | 3,121 | -64,547 |
| Cash and cash equivalents at beginning of period | 35,685 | 25,803 | 87,229 | - |
| Cash and cash equivalents at end of period | 8,356 | 35,685 | 25,803 | - |
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. (CLYM)